Search research articles
Contact Us
Filters
Showing results (101-110 of 121) with videos related to
Page
of 13
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N I Cherny, U Dafni, J Bogaerts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2017
Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'
N I Cherny, U Dafni, J Bogaerts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio
N I Cherny, U Dafni, J Bogaerts, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2008
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)
C M L van Herpen, L D Locati, J Buter, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2012
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer
H Bonnefoi, K Zaman, M Debled, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2000
Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer
U Gatzemeier, J von Pawel, M Gottfried, et al.
ESMO Open
|
December 1, 2016
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
N I Cherny, R Sullivan, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2018
Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al
N I Cherny, U Dafni, M Piccart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2002
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
R Rosell, U Gatzemeier, D C Betticher, et al.
Breast Cancer Research and Treatment
|
January 29, 2014
Mammographic screening detects low-risk tumor biology breast cancers
C A Drukker, M K Schmidt, E J T Rutgers, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 121) with videos related to
Sort By:
Page
of 13
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N I Cherny, U Dafni, J Bogaerts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 22, 2017
Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'
N I Cherny, U Dafni, J Bogaerts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Reply to the letter to the editor 'Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?' by Del Paggio
N I Cherny, U Dafni, J Bogaerts, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2008
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)
C M L van Herpen, L D Locati, J Buter, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 25, 2012
An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer
H Bonnefoi, K Zaman, M Debled, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2000
Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer
U Gatzemeier, J von Pawel, M Gottfried, et al.
ESMO Open
|
December 1, 2016
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
N I Cherny, R Sullivan, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2018
Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al
N I Cherny, U Dafni, M Piccart, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2002
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial
R Rosell, U Gatzemeier, D C Betticher, et al.
Breast Cancer Research and Treatment
|
January 29, 2014
Mammographic screening detects low-risk tumor biology breast cancers
C A Drukker, M K Schmidt, E J T Rutgers, et al.
Page
of 13